AZN Receives US FDA Approval for Imfinzi Combination Regimen in Muscle-Invasive Bladder Cancer
· The NYC Memo
AstraZeneca announced that the U.S. Food and Drug Administration approved perioperative Imfinzi in combination with neoadjuvant enfortumab vedotin for patients with muscle-invasive bladder cancer. The regulatory approval was based on data from the Phase III VOLGA trial, which demonstrated a 49% reduction in the risk of recurrence and a 42% reduction in the risk of death.